Your browser doesn't support javascript.
loading
Gastric cancer risk in the elderly is associated with omeprazole use and inversely associated with aspirin use.
Gingold-Belfer, Rachel; Issa, Nidal; Boltin, Doron; Beloosesky, Yichayaou; Koren-Morag, Nira; Meyerovitch, Joseph; Sharon, Eran; Peleg, Noam; Schmilovitz-Weiss, Hemda.
Afiliación
  • Gingold-Belfer R; Gastroenterology Division, Rabin Medical Center - Beilinson Hospital, Petach Tikva.
  • Issa N; Faculty of Medicine, Tel Aviv University, Tel Aviv.
  • Boltin D; Faculty of Medicine, Tel Aviv University, Tel Aviv.
  • Beloosesky Y; Department of Surgery B, Rabin Medical Center - Hasharon Hospital.
  • Koren-Morag N; Gastroenterology Division, Rabin Medical Center - Beilinson Hospital, Petach Tikva.
  • Meyerovitch J; Faculty of Medicine, Tel Aviv University, Tel Aviv.
  • Sharon E; Faculty of Medicine, Tel Aviv University, Tel Aviv.
  • Peleg N; Department of Geriatrics, Rabin Medical Center - Beilinson Hospital, Petach Tikva.
  • Schmilovitz-Weiss H; Faculty of Medicine, Tel Aviv University, Tel Aviv.
Eur J Gastroenterol Hepatol ; 35(9): 968-973, 2023 09 01.
Article en En | MEDLINE | ID: mdl-37505975
BACKGROUND: The association between long-term omeprazole use and gastric cancer (GC) risk is controversial. The aim of this study was to investigate the incidence of GC in elderly community-dwelling omeprazole chronic users with/without aspirin compared to non-users. METHODS: The registry of a large health management organization was searched for all community-dwelling members aged ≥65 years from January 2002 to December 2016. Data on demographics, background parameters, and chronic omeprazole and aspirin use (>11 prescriptions/year) were retrieved. Those diagnosed with new-onset GC during the study period (from January 2003) were identified. RESULTS: Of 51 405 subjects who met the inclusion criteria, 197 were diagnosed with GC during a mean follow-up period of 8.74 ±â€…4.16 years. This group accounted for 0.7% of PPI chronic users (72/11 008) and 0.3% (125/40 397) of nonusers (P < 0.001). GC risk was directly associated with omeprazole chronic use [hazard ratio (HR) 2.03, 95% confidence interval (CI): 1.51-2.73, P < 0.001] and inversely associated with aspirin chronic use (HR 0.55, 95% CI: 0.40-0.75, P < 0.001). Each year of omeprazole use increased GC risk by 9%, and each year of aspirin use decreased GC risk by 10% among omeprazole chronic users. The lowest rate of GC was found in omeprazole nonusers/ aspirin chronic users, and the highest, in omeprazole chronic users/aspirin nonusers. CONCLUSION: Higher GC rate was associated with omeprazole chronic use and inversely associated with aspirin chronic use relative to omeprazole nonuse in community-dwelling elderly.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Aspirina Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans Idioma: En Revista: Eur J Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Aspirina Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans Idioma: En Revista: Eur J Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido